Figure 5

Ixmyelocel-T promotes blood flow recovery in the rat hind-limb model. (A) Treatment with ixmyelocel-T significantly increased blood flow recovery measured by laser Doppler (n = 4). (B) Treatment with ixmyelocel-T significantly increased capillary density in the ischemic limb (10×) (n = 4). (C, D) Treatment with ixmyelocel-T significantly increased plasma nitrates (n = 4) and platelet-derived growth factor (PDGF; n = 3). (E) Treatment with ixmyelocel-T increased gene expression of vascular endothelial growth factor (VEGF) in the ischemic limb (n = 4). (F) Gene expression of the anti-inflammatory cytokine interleukin (IL)-10 is significantly increased in the ischemic limb of the ixmyelocel-T-treated group (n = 4). (G) Circulating levels of IL-10 trended upwards in the ixmyelocel-T-treated group (n = 4). (H) Plasma levels of thiobarbituric acid reactive substances were significantly decreased in the ixmyelocel-T-treated group (n = 4). Values presented as mean ± standard error of the mean. *P <0.05 versus vehicle. Magnification: 10×. IXT, ixmyelocel-T; MDA, malondialdehyde.